Skip to main content
Toggle navigation
Login
Search
Home
Tweets by ASCPT 2023 Annual Meeting
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
4
PWI-002
4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.
Favorite
PII-094
4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.
Favorite
A
PI-093
A COMPREHENSIVE MIDD APPROACH TO ASSESS THE SAFETY AND EFFICACY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS FOR EARLY DECISION MAKING.
Favorite
PI-010
A DDI STUDY TO EVALUATE THE EFFECT OF MULTIPLE ORAL ADMINISTRATION OF RIFAMPICIN ON THE PHARMACOKINETICS OF VALEMETOSTAT IN HEALTHY PARTICIPANTS.
Favorite
EP-032
A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS.
Favorite
PT-014
A GLOBAL PROTEOMICS ANALYSIS OF THE ONTOGENY OF THE BLOOD-BRAIN BARRIER.
Favorite
PT-006
A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS.
Favorite
PWII-002
A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.
Favorite
PII-020
A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.
Favorite
PI-033
A MECHANISTIC PK/PD MODEL OF AZD0171 (ANTI-LIF) TO SUPPORT PHASE 2 DOSE SELECTION.
Favorite
PII-123
A MODEL-BASED META-ANALYSIS TO ASSESS THE SIMILARITIES AND DIFFERENCES OF CLINICAL SAFETY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS.
Favorite
PI-034
A MULTI-PURPOSE FIRST-IN-HUMAN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-777991, AN ORAL C-X-C MOTIF CHEMOKINE RECEPTOR 3 (CXCR3) ANTAGONIST.
Favorite
PT-025
A NOVEL REGULATORY VARIANT PROMOTES CYP2D6 ALTERNATIVE SPLICING AND REDUCES FULL-LENGTH CYP2D6 PROTEIN LEVELS IN LIVER SAMPLES.
Favorite
EP-033
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Favorite
LB-003
A PHASE I, RANDOMIZED, OPEN-LABEL, CROSSOVER, FIXED-SEQUENCE STUDY TO EVALUATE THE PK, D0SE-PROPORTIONALITY, BIOAVAILABILITY, AND TOLERABILITY OF SUBCUTANEOUS LEVOTHYROXINE SODIUM (XP-8121) IN HEALTHY ADULT SUBJECTS.
Favorite
PI-074
A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).
Favorite
PI-035
A POPULATION PHARMACOKINETIC ANALYSIS OF ESCITALOPRAM AND THE EFFECT OF CYP2C19 ON CLEARANCE IN CHILDREN AND ADOLESCENTS.
Favorite
LB-007
A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR CARFILZOMIB IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA.
Favorite
PI-094
A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF SEPSIS-INDUCED AUGMENTED RENAL CLEARANCE.
Favorite
PI-021
A RETROSPECTIVE GENOME-WIDE ASSOCIATION STUDY OF ANTIPSYCHOTIC DRUG RESPONSE IN PEDIATRIC PATIENTS WITH PSYCHIATRIC ILLNESS IN A RURAL HEALTHCARE SETTING.
Favorite
EP-004
A SINGLE CENTRE, PROSPECTIVE STUDY TO EVALUATE THE EFFECT OF DOUBLE CARBAPENEM BASED COLISTIN THERAPY VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE AT A TERTIARY CARE HOSPITAL IN INDIA.
Favorite
PWII-004
A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.
Favorite
PII-107
A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.
Favorite
LB-015
A TRANSLATIONAL COMPUTATIONAL MODEL OF ALLERGEN CHALLENGE TO SUPPORT THE CLINICAL DEVELOPMENT OF AN INTRANASALLY ADMINISTERED BACTERIAL LYSATE IN MILD ASTHMA.
Favorite
PI-036
AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS.
Favorite
PII-120
AN INTERIM PHARMACOKINETIC (PK) ANALYSIS OF CANNABINOIDS IN SERUM OF VOLUNTEERS RECEIVING COSMETIC HEMP EXTRACT VIA THE ORAL OR TOPICAL ROUTES.
Favorite
EP-005
AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB.
Favorite
PI-101
AN OPEN-LABEL SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
Favorite
EP-006
AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF COADMINISTRATION OF SOTORASIB ON THE PHARMACOKINETICS OF ROSUVASTATIN, A BREAST CANCER RESISTANCE PROTEIN SUBSTRATE, IN HEALTHY SUBJECTS.
Favorite
PI-037
AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON INCB000928 PHARMACOKINETICS WHEN ADMINISTERED ORALLY IN HEALTHY PARTICIPANTS.
Favorite
PI-022
ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL.
Favorite
PWI-005
APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Favorite
PII-095
APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Favorite
PWII-005
APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Favorite
PII-124
APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Favorite
PI-075
APPLICATION OF MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR INSULIN.
Favorite
PI-038
APPLICATION OF MODELING AND SIMULATION TO EXTRAPOLATE THERAPEUTIC BUROSUMAB DOSING REGIMENS FOR SUBJECTS WITH PEDIATRIC TUMOR-INDUCED OSTEOMALCIA.
Favorite
PI-039
APPLICATION OF POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING TO SUPPORT DOSAGE REGIMEN OF FESOTERODINE IN PEDIATRICS WITH NEUROLOGICAL DETRUSOR OVERACTIVITY.
Favorite
PI-040
ASSESSING THE GOLDENSEAL-METFORMIN PHARMACOKINETIC INTERACTION IN TYPE 2 DIABETICS.
Favorite
E-003
ASSESSMENT OF TREATMENT PATHS FOR OUD PATIENTS AFTER AN ACUTE OUD EVENT.
Favorite
RWE-005
ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).
Favorite
PI-001
ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).
Favorite
PT-009
ASSOCIATION BETWEEN TACROLIMUS AND CYP3A5 GENOTYPE IN PEDIATRIC KIDNEY TRANSPLANT.
Favorite
B
PI-041
BENEFIT-RISK OF FLAT-DOSING OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN THORACIC CANCER IMMUNOTHERAPY (1L METASTATIC NON-SMALL-CELL LUNG CANCER AND 1L UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA).
Favorite
PII-026
BILE ACIDS AS POTENTIAL BIOMARKERS TO ASSESS LIVER IMPAIRMENT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD).
Favorite
PI-095
BLINATUMOMAB TRIMER FORMATION - INSIGHTS FROM A MECHANISTIC PKPD MODEL ON THE IMPLICATIONS FOR SWITCHING FROM INFUSION TO SUBCUTANEOUS DOSING REGIMEN IN ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN’S LYMPHOMA.
Favorite
PI-042
BUDESONIDE EMBEDDED ALGINATE THIN FILMS SHOW TUNABLE SUSTAINED RELEASE.
Favorite
PT-029
BUILDING A TELEHEALTH PHARMACOGENETIC TESTING PROGRAM IN RURAL AND PEDIATRIC PSYCHIATRY.
Favorite
C
PI-076
CANNABIDIOL EXPOSURES IN BREASTFED INFANTS COMPARED TO CHILDREN AS PREDICTED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING.
Favorite
PT-017
CARDIOVASCULAR SAFETY OF CARFILZOMIB IN KOREA: RETROSPECTIVE COHORT STUDY USING A NATIONWIDE ADMINISTRATIVE CLAIM DATABASE.
Favorite
PI-085
CEFEPIME PHARMACOKINETICS IN CRITICALLY ILL CHILDREN UNDERGOING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT).
Favorite
EP-007
CENTRAL ADMINISTRATION OF COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT PEPTIDE REDUCES CISPLATIN-INDUCED EMESIS AND C-FOS EXPRESSION IN SUNCUS MURINUS.
Favorite
PI-023
CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.
Favorite
PWIII-003
CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.
Favorite
PI-043
CHARACTERIZATION OF GEMTUZUMAB OZOGAMICIN PHARMACOKINETICS IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING FRACTIONATED DOSING REGIMEN.
Favorite
PI-083
CHARACTERIZATION OF THE US FOOD AND DRUG ADMINISTRATION POST-MARKETING COMMITMENTS AND REQUIREMENTS FOR PREGNANCY AND LACTATION.
Favorite
PI-097
CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Favorite
RWE-010
CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Favorite
PI-011
CHARACTERIZING THE RELATIONSHIP BETWEEN CELLULAR KINETICS AND RESPONSE TO SUPPORT DOSING RECOMMENDATIONS FOR CD19-TARGETED 19(T2)28Z1XX CELL THERAPY.
Favorite
PI-024
CHRONIC NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) USE INCREASES GASTRIC TOXICITY: A PHARMACOGENOMIC ANALYSIS.
Favorite
PT-028
CLINICAL ASSESSMENT OF THE DRUG INTERACTION POTENTIAL OF THE PSYCHOTROPIC NATURAL PRODUCT KRATOM (MITRAGYNA SPECIOSA).
Favorite
PI-044
CLINICAL DRUG–DRUG INTERACTION STUDIES TO EVALUATE THE EFFECTS OF BEMPEDOIC ACID, A SMALL-MOLECULE INHIBITOR OF ATP CITRATE LYASE, ON THE PHARMACOKINETICS OF CONCOMITANT STATIN THERAPIES.
Favorite
PI-012
CLINICAL EFFICACY OF CAR-T AND CAR-NK FOR THE TREATMENT OF HEMATOLOGIC AND SOLID TUMOR MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Favorite
PI-045
COMPARATIVE PHARMACOKINETICS BETWEEN DA-2811, A DAPAGLIFLOZIN PRODRUG FORMULATION, AND CONVENTIONAL DAPAGLIFLOZIN TABLET.
Favorite
PI-046
COMPARISON OF A COLORIMETRIC ASSAY AND ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY FOR QUANTIFYING PARACETAMOL PLASMA CONCENTRATIONS: DESIGN OF A GERIATRIC PHARMACOKINETICS STUDY.
Favorite
PI-086
COMPARISON OF DISEASE CHARACTERISTICS IN ADULTS AND CHILDREN WITH TYPE 2 DIABETES MELLITUS: IMPLICATION FOR ANTIDIABETIC DRUG DEVELOPMENT IN CHILDREN.
Favorite
PI-047
COMPARISON OF PATIENT-CENTRIC MICROSAMPLING VS. TRADITIONAL BLOOD SAMPLING FOR PHARMACOKINETIC ANALYSIS OF ABROCITINIB.
Favorite
PI-048
COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF HIP1802 AND NEXIUM®: A RANDOMIZED, OPEN-LABEL, MULTIPLE DOSE, CROSSOVER TRIAL.
Favorite
PI-013
COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB + BINIMETINIB.
Favorite
PI-049
COMPARISON OF THE ACID SUPPRESSION EFFECTS BETWEEN LOW-DOSE ESOMEPRAZOLE AND FAMOTIDINE IN HEALTHY SUBJECTS.
Favorite
PII-001
COMPARISON OF THE IMMUNOGENICITY RISK OF BIOTHERAPEUTICS ADMINISTERED VIA INTRAVENOUS VS. SUBCUTANEOUS ROUTE OF ADMINISTRATION.
Favorite
PI-050
COMPARISON OF THE SYSTEMIC EXPOSURE AND PREDICTED INHIBITION OF PHARMACODYNAMIC CYTOKINE RESPONSE BY SYSTEMIC AND LOCALLY ACTING JAK INHIBITORS.
Favorite
PT-011
COMPUTATIONAL SYSTEMS PHARMACOLOGY OF ANTIBODY-DRUG CONJUGATES.
Favorite
PII-053
CONCENTRATION-QT MODELING ANALYSIS OF GEMTUZUMAB OZOGAMICIN FOLLOWING FRACTIONATED DOSING REGIMEN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.
Favorite
PI-051
CONCENTRATION-QTC ANALYSIS TO ASSESS THE EFFECT OF THE GS-5718 ON CARDIAC REPOLARIZATION.
Favorite
RWE-002
CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.
Favorite
PT-013
CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.
Favorite
PII-121
CONTRIBUTION OF INFLAMMATION AND OBESITY TO VARIABILITY IN MIDAZOLAM PHARMACOKINETICS IN CHILDREN.
Favorite
PI-052
CYCLOPHOSPHAMIDE POPULATION PHARMACOKINETICS IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Favorite
D
PI-014
DETERMINATION OF ABSOLUTE BIOAVAILABILITY OF QUIZARTINIB USING A MICROTRACER.
Favorite
PI-053
DEVELOPING A MECHANISTIC MODEL OF IL-15 MEDIATED NK CELL PROLIFERATION WITH IMPLICATIONS IN IMPROVING CAR NK CELL THERAPY EFFICACY.
Favorite
PI-077
DEVELOPMENT AND VERIFICATION OF A PYRIDOXIC ACID PBPK MODEL TO EVALUATE BIOMARKER INFORMED ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3 INHIBITION.
Favorite
PII-002
DEVELOPMENT OF A MULTISCALE MECHNISM-BASED CELLULAR KINETIC-PHARMACODYNAMIC (CK-PD) MODEL FOR DUAL-TARGETED BICISTRONIC CAR-T CELL THERAPY.
Favorite
PI-054
DEVELOPMENT OF A PHARMACOKINETIC-PHARMACODYNAMIC MODEL FOR MRNA-0184, AN INVESTIGATIONAL MRNA THERAPEUTIC ENCODING HUMAN RELAXIN-2-VLK FOR THE TREATMENT OF HEART FAILURE.
Favorite
LB-008
DEVELOPMENT OF HOLISTIC EXPOSURE-TOXICITY RELATIONSHIPS FOR MMAE-BASED ADCS: A GENERALIZED PK/PD MODEL.
Favorite
PI-096
DEVELOPMENT OF IMMUNO-ONCOLOGY (IO) QSP PLATFORM MODEL FOR EFFICACY PREDICTION OF CHECKPOINT INHIBITORS (CPI) AND ADC COMBINATION THERAPY IN PHASE II/III CLINICAL TRIALS.
Favorite
PT-023
DEVELOPMENT OF INTRANASAL PHYSIOLOGICALLY BASED NOSE TO BRAIN MODEL AND ITS APPLICATION TO CHARACTERIZE IN NEUROEPO ABSORPTION VIA NASAL ROUTE AND DISTRIBUTION TO LUMBAR CSF IN HEALTHY NON-HUMAN PRIMATES (CYANOMOLGUS MONKEY).
Favorite
EP-013
DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE AND OPTIMAL DOSE RECOMMENDATION FOR ELDERLY WITH DIABETES MELLITUS IN KOREAN TUBERCULOSIS PATIENTS.
Favorite
PII-125
DEVELOPMENT OF RHEUMATOID ARTHRITIS QSP MODEL FOR TRIAL SIMULATION AND PREDICTING RESPONSE TO NOVEL COMBINATIONS.
Favorite
PI-015
DEVELOPMENT OF USER-FRIENDLY BAYESIAN PREDICTIVE PLATFORM FOR BLOOD BORON-10 PHARMACOKINETICS FOLLOWING INTRAVENOUS INFUSION OF [10B]L-4-BORONOPHENYLALANINE.
Favorite
PI-087
DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.
Favorite
PWIV-003
DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.
Favorite
PT-027
DO GLUCOSE-LOWERING DRUGS AFFECT DRUG METABOLISM AND WARFARIN EFFICACY?
Favorite
PI-025
DOCUMENTATION OF RESULTS AND MEDICATION PRESCRIBING AFTER COMBINATORIAL PSYCHIATRIC PHARMACOGENETIC TESTING.
Favorite
PI-055
DOSE SELECTION FOR BRIGATINIB TO SUPPORT PEDIATRIC DEVELOPMENT.
Favorite
PI-056
DOSE SELECTION FOR MITAPIVAT PEDIATRIC PHASE 3 STUDIES USING POPULATION PHARMACOKINETIC MODELING AND SIMULATION.
Favorite
PI-057
DOSE–RESPONSE MODEL PREDICTIONS OF THE PHARMACODYNAMIC EFFECT OF BEMPEDOIC ACID, A COMPETITIVE INHIBITOR OF ATP CITRATE LYASE, IN COMBINATION WITH EZETIMIBE AND STATINS.
Favorite
PII-011
DRUG-DRUG INTERACTION BETWEEN THE NOVEL SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR, DWP16001, WITH GEMIGLIPTIN AND METFORMIN IN HEALTHY SUBJECTS.
Favorite
PI-058
DRUG-DRUG INTERACTION POTENTIAL OF MAVACAMTEN WITH ORAL CONTRACEPTIVES: RESULTS FROM A CLINICAL PHARMACOKINETIC STUDY.
Favorite
E
PI-059
EARLY CLINICAL PK/PD MODELING AND SIMULATION OF ALPN-303, A POTENT DUAL BAFF/APRIL ANTAGONIST, TO SUPPORT FIRST-IN-DISEASE CLINICAL TRIALS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER B CELL-RELATED DISEASES.
Favorite
PII-006
EARLY PHARMACODYNAMIC BIOMARKER DEVELOPMENT IN ADOLESCENTS WITH EATING DISORDERS.
Favorite
PI-060
ECULIZUMAB COMPLEMENT-MEDIATED PK/PD MODEL-INFORMED SIMULATIONS REVEAL THE NEED FOR ALTERNATIVE DOSING REGIMENS DURING MAINTENANCE THERAPY FOR STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA).
Favorite
PI-061
EFFECT OF A MODERATE CYP3A4 INDUCER ON ENCORAFENIB IN COMBINATION WITH BINIMETINIB IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS.
Favorite
PI-062
EFFECT OF ACT-539313, A SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, ON THE CYTOCHROME P450 2C9, 2C19, AND 3A4 SUBSTRATES FLURBIPROFEN, OMEPRAZOLE, AND MIDAZOLAM USING A COCKTAIL APPROACH.
Favorite
PII-054
EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS.
Favorite
PI-026
EFFECT OF CYP2D6 PHENOTYPE ON PHARMACOKINETICS OF DWN12088, A NOVEL PROLYL-TRNA SYNTHETASE INHIBITOR, IN A FIRST-IN HUMAN STUDY.
Favorite
PWIII-004
EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.
Favorite
PI-063
EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.
Favorite
PI-027
EFFECT OF GENETIC VARIANTS IN TSPYL ON THE PHARMACOKINETICS OF CYCLOSPORINE.
Favorite
PI-016
EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS.
Favorite
E-001
EFFECT OF PAROXETINE OR QUETIAPINE COMBINED WITH OXYCODONE VS OXYCODONE ALONE ON VENTILATION DURING HYPERCAPNIA: A RANDOMIZED CLINICAL TRIAL.
Favorite
PII-122
EFFECT OF THE CHOLESTYRAMINE-INDUCED ALTERATION OF BILE ACID POOL IN THE GUT ON THE PHARMACODYNAMICS OF METFORMIN: AN EXPLORATORY STUDY.
Favorite
LB-016
EFFECTIVENESS OF HIGH DOSE VERSUS STANDARD DOSE INFLUENZA VACCINES IN OLDER ADULTS : INSIGHTS FROM A MULTI-STRAIN MODELING APPROACH TAKING ANTIGENIC DISTANCE INTO ACCOUNT.
Favorite
LB-006
EFFECTS OF ANTIOXIDANTS IN DRUGS PRODUCTS ON INTESTINAL DRUG TRANSPORTERS.
Favorite
PI-064
EFFECTS OF GLPG3970 ON SULFASALAZINE AND METHOTREXATE PHARMACOKINETICS IN HEALTHY ADULTS: RESULTS OF TWO OPEN-LABEL, PHASE I, DRUG–DRUG INTERACTION STUDIES.
Favorite
PI-081
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (ETI) -INDUCED REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN HEPG2 CELLS: A POTENTIAL MECHANISM OF DRUG-INDUCED LIVER INJURY (DILI)
Favorite
PI-017
ELIGIBILITY CRITERIA OF EARLY PHASE ONCOLOGY TRIALS.
Favorite
EP-036
ESTIMATING TARGET ENGAGEMENT USING SINGLE POST-DOSE TIMEPOINT TO SUPPORT FURTHER CLINICAL DEVELOPMENT.
Favorite
EP-014
ESTIMATION OF NOVEL BISPECIFIC T-CELL ENGAGER (BiTE®) MOLECULE PHARMACOKINETICS IN CYNOMOLGUS MONKEY FROM STRUCTURALLY-SIMILAR BiTE MOLECULE DATA.
Favorite
PI-066
ETEPLIRSEN, GOLODIRSEN, AND CASIMERSEN SHOW CONSISTENT CLINICAL PHARMACOLOGY PROPERTIES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.
Favorite
LB-012
ETHANOL AS AN EXCIPIENT IN DRUG FORMULATIONS ADMINISTERED TO NEONATES: PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO INFORM SAFETY.
Favorite
PI-103
EVALUATING THE CONSISTENCY AND EXTENT OF IMMUNOGENICITY REPORTING FOR RECENTLY APPROVED BIOLOGICS.
Favorite
PI-028
EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Favorite
PWIII-005
EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Favorite
EP-028
EVALUATING THE UTILITY OF PROTEOMICS FOR THE IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS OF IFNΒ-1A BIOLOGICS.
Favorite
PI-067
EVALUATION OF CREATININE-BASED RENAL FUNCTION ESTIMATION EQUATIONS BY PHARMACOMETRIC ANALYSIS FOR ANTIBIOTICS.
Favorite
PII-111
EVALUATION OF SEX DIFFERENCES IN MEDICATION PRESCRIBING RECOMMENDATIONS AND OCCURRENCE OF ADVERSE EVENTS.
Favorite
PI-029
EVALUATION OF THE G6PD VARIANT C.376A>G ACTIVITY IN ALL OF US.
Favorite
EP-027
EXAMINING THE REGIONAL IMPACT OF FENTANYL ON INFLAMMATORY MEDIATORS WITHIN THE BRAIN IN THE SETTING OF HIV.
Favorite
PII-007
EXPERIENCES OF CEREBROSPINAL FLUID COLLECTION, EITHER BY SERIAL SAMPLING OR BY LUMBER PUNCTURES, IN CLINICAL PHARMACOLOGY RESEARCH.
Favorite
EP-015
EXPLAINING INTERPATIENT VARIABILITY OF ADALIMUMAB RESPONSE IN CHRONIC PLAQUE PSORIASIS BY PHARMACOKINETIC-PHARMACODYNAMIC MODELLING: RESULTS FROM THE OPTIMAP STUDY.
Favorite
PI-084
EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.
Favorite
PWIV-001
EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.
Favorite
PI-068
EXPOSURE-RESPONSE (E-R) OF DUPILUMAB IN PAEDIATRIC PATIENTS WITH MODERATE-TO-SEVERE ASTHMA.
Favorite
PI-069
EXPOSURE-RESPONSE MODELING STRATEGIES IN ONCOLOGY: IMPACT OF DOSE REDUCTIONS ON INTERPRETATION OF RESULTS.
Favorite
PI-070
EXPOSURE-TARGETED MELPHALAN DOSING INDIVIDULIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT.
Favorite
PT-003
EXPRESSION OF ABCB1 IS DECREASED IN PLACENTA OF WOMEN WITH AUTOIMMUNE DISEASE AND IN CYTOKINE- TREATED PLACENTAL EXPLANTS.
Favorite
E-004
EXTRAPOLATION OF EFFICACY OF A DEXTROAMPHETAMINE TRANSDERMAL SYSTEM (d-ATS) FROM PEDIATRIC (PED) TO ADULT POPULATIONS USING PHARMACOKINETIC (PK) MODELING.
Favorite
F
PII-008
FC RECEPTOR MODULATION AND POTENTIAL IMPACT ON CLEARANCE OF IMMUNE CHECKPOINT INHIBITORS IN CANCER CACHEXIA.
Favorite
PI-002
FENO AND SMOKING HISTORY, NOT EOSINOPHILIA, MAY PREDICT THE EFFICACY OF TIOTROPIUM (SPIRIVA RESPIMAT) IN UNCONTROLLED ASTHMA PATIENTS DESPITE ICS/LABA TREATMENT: A PILOT STUDY.
Favorite
PI-018
FIRST-IN-HUMAN (FIH) HEALTHY VOLUNTEER (HV) STUDIES FOR ONCOLOGY THERAPEUTICS: A FRAMEWORK OF APPLICATION IN EARLY ONCOLOGY CLINICAL DEVELOPMENT.
Favorite
PII-012
FROM RIFAMPIN TO CARBAMAZEPINE: HOW TO PROPERLY MANAGE SAFETY IN A CHANGING DRUG-DRUG-INTERACTION TRIAL LANDSCAPE.
Favorite
PT-020
FUNCTIONAL CHARACTERIZATION OF ELAVL2 REVEALED THE ROLE OF POST-TRANSCRIPTIONAL REGULATION IN PSYCHIATRIC DISORDERS AND ANTIDEPRESSANT TREATMENT RESPONSE.
Favorite
E-002
FURTHER EVIDENCE ON ABCB1 DRUG TRANSPORTER IN THE RESPONSE TO TEMOZOLOMIDE, CARMUSTINE AND LOMUSTINE IN GLIOBLASTOMA MULTIFORME.
Favorite
G
EP-016
GATIFLOXACIN EXPOSURE IN THE LESION AS TARGET SITE OF GATIFLOXACIN IN A RABBIT MODEL OF TUBERCULOSIS: COMPARISON WITH THE OUTCOMES FROM THE PHASE III OFLOTUB TRIAL.
Favorite
PII-046
GENOME WIDE ASSOCIATION STUDY (GWAS) OF SECOND-GENERATION ANTIPSYCHOTICS (SGA)-INDUCED METABOLIC SYNDROME (METS) IN BIOME BIOBANK.
Favorite
PII-127
GERIATRIC REMOTE INITIATIVE (GeRI): IMPLEMENTING REMOTE ASSESSMENTS OF TOXICITY AND FRAILTY FOR OLDER ADULTS WITH CANCER.
Favorite
RWE-004
GERIATRIC REMOTE INITIATIVE (GeRI): IMPLEMENTING REMOTE ASSESSMENTS OF TOXICITY AND FRAILTY FOR OLDER ADULTS WITH CANCER.
Favorite
H
PI-071
HOLISTIC INTEGRATION OF POPULATION PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY TO DEFINE RECOMMENDED DOSE FOR EXPANSION OF ATR INHIBITOR, M1774: AN ILLUSTRATION OF MODEL-INFORMED EARLY ONCOLOGY DRUG DEVELOPMENT.
Favorite
PII-128
HOW DOES CLEARANCE OF ILLICITLY MANUFACTURED FENTANYL AFFECT WITHDRAWAL DURING EARLY BUPRENORPHINE TREATMENT?
Favorite
PII-108
HUMAN RADIOLABELED MASS BALANCE STUDIES SUPPORTING NEW DRUGS APPROVAL BY THE FDA BETWEEN 2019 TO JUNE 2022.
Favorite
EP-010
HYPOXIA INDUCIBLE FACTOR-1A POLYMORPHISMS ASSOCIATED WITH ADVANCED CHRONIC KIDNEY DISEASE.
Favorite
I
EP-029
IDENTIFICATION OF A SAFE AND TOLERABLE CARBAMAZEPINE DOSING PARADIGM THAT FACILITATES EFFECTIVE CYP3A INDUCTION EVALUATION.
Favorite
PI-019
IDENTIFICATION OF S100A9 AS A THERAPEUTIC TARGET IN PACLITAXEL-INDUCED PERIPHERIAL NEUROPATHY (PIPN).
Favorite
RWE-003
IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.
Favorite
PII-030
IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.
Favorite
LB-009
IMPACT OF INTRAMUSCULAR INJECTION SITE ON SOTROVIMAB PHARMACOKINETICS.
Favorite
PWIV-004
IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.
Favorite
PI-088
IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.
Favorite
PI-020
IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC).
Favorite
PI-072
IN VITRO AND IN VIVO POTENTIAL OF ZURANOLONE TO CAUSE CYP-MEDIATED DRUG-DRUG INTERACTIONS.
Favorite
PII-013
IN VITRO, IN SILICO, AND CLINICAL INVESTIGATIONS OF BLU-5937 AS PERPETRATOR OF DRUG-DRUG INTERACTIONS.
Favorite
PII-104
INDIVIDUAL DOSE OPTIMIZATION FOR SOMATROGON BY MODELING AND SHINY INTERFACE.
Favorite
EP-025
INDUCED PLURIPOTENT STEM CELLS (IPSCS) AS A MODEL TO STUDY THIOPURINE INDUCED PANCREATITIS: PERSONALIZATION OF THERAPY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Favorite
PII-047
INFLAMMATION DRIVEN INHIBITION OF CYP2C19 METABOLISM OF VORICONAZOLE IN THE TREATMENT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
Favorite
PT-008
INFLUENCE OF MCT6 ON PLATINUM DISPOSITION AND OTOTOXICITY.
Favorite
PII-003
INTEGRATED CELLULAR KINETIC (CK) – PHARMACODYNAMIC (PD) ANALYSIS FOR FIRST IN HUMAN DOSE-ESCALATION STUDY OF TAK-102: A GPC3 TARGETED AUTOLOGOUS CAR-T CELLS ARMORED WITH IL-7 AND CCL19.
Favorite
EP-002
INTEGRATED METABOLOMICS ANALYSIS REVEALS MECHANISTIC INSIGHTS INTO THE ANCESTRAL DIFFERENCES IN PLASMA RENIN ACTIVITY AMONG PATIENTS WITH HYPERTENSION AND THIAZIDE DIURETICS BLOOD PRESSURE LOWERING EFFECTS.
Favorite
PI-073
INTEGRATED MODEL-BASED ANALYSIS UTILIZING CO-EXPRESSED CHECKPOINT INHIBITOR DATA TO INFORM THE RECOMMENDED DOSE FOR EXPANSION (RDE) OF ANTI-TIGIT MAB M6223.
Favorite
PII-048
INTERETHNIC DIFFRENCE IN (S)-WARAIN PHARMACOKINETICS AND EXTENT OF ANTICOAGULATION BETWEEN ETHIOPIAN AND NON-ETHIOPIAN JEWS.
Favorite
PI-099
INTERNATIONAL COMPARISON OF THE NUMBER OF PHASE 3 CLINICAL TRIALS FOR COVID-19.
Favorite
PII-055
INVESTIGATING THE EFFECT OF INFORMATIVE CENSORING ON THE KAPLAN-MEIER ESTIMATE OF ENDPOINTS IN ONCOLOGY CLINICAL TRIALS.
Favorite
PII-034
INVESTIGATION OF DRUG COMBINATIONS IN CANCER THROUGH UNBIASED IDENTIFICATION OF RECURRING DRUG RESPONSE PATTERNS IN CELL LINES.
Favorite
PII-105
INVESTIGATION OF THE BIOTRANSFORMATION OF TRIHEXYPHENIDYL AND APPLICATION TO DYSTONIC CEREBRAL PALSY.
Favorite
L
PII-056
LENACAPAVIR PHARMACOKINETICS AND DDI POTENTIAL WITH CO-ADMINISTERED ANTIRETROVIRALS IN PEOPLE WITH HIV.
Favorite
PI-078
LEVERAGING A DERMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF A TOPICAL CREAM TO EXPLORE THE BIOEQUIVALENCE SAFE SPACE FOR INFLUENTIAL FORMULATION ATTRIBUTES.
Favorite
PII-027
LEVERAGING MACHINE LEARNING (ML) TO QUANTIFY CHANGES IN CELLULAR LOCALIZATION AND ZONAL DISTRIBUTION OF TRANSPORTERS IN LIVER TISSUE FROM PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD).
Favorite
PI-079
LEVERAGING PBPK DDI APPLICATION TO ENLIGHTEN THE MECHANISMS OF THE INTERACTION BETWEEN PHENYTOIN AND OMEPRAZOLE AND POTENTIAL IMPACT IN EPILEPTIC PATIENTS.
Favorite
PI-080
LEVERAGING PBPK-BASED ANALYSIS TO SUPPORT AN ADAPTIVE TRIAL DESIGN IN CHILDREN.
Favorite
PII-057
LIMITED DRUG INTERACTION SUPPORTED BY PBPK MODELLING OF ETRUMADENANT (AB928), A NOVEL DUAL ADENOSINE RECEPTOR ANTAGONIST, UNDER COADMINISTRATION WITH A STRONG CYP3A4 AND P-GP INHIBITOR (ITRACONAZOLE) IN HEALTHY PARTICIPANTS.
Favorite
PII-019
LINEZOLID REACHES TARGET SITE IN TUBERCULOUS MENINGITIS PATIENTS IRRESPECTIVE OF STANDARD OR HIGH RIFAMPIN DOSE.
Favorite
PII-031
LONGITUDINAL EFFICACY ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) FOR THE TREATMENT OF ACUTE AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR DISORDER.
Favorite
PII-058
LOW SENSITIVITY OF TEPOTINIB TO DRUG-DRUG INTERACTIONS WITH CYP3A4 AND P-GP MODULATORS.
Favorite
M
EP-026
MACHINE LEARNING FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELING.
Favorite
PII-035
MACHINE LEARNING-BASED DOSE OPTIMIZATION DESIGN INCORPORATING EXPOSURE-RESPONSE RELATIONSHIP IN CELL THERAPY.
Favorite
PII-112
MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Favorite
PWI-003
MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Favorite
PT-005
MAJOR POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICAID-INSURED CHILDREN IN THE OUTPATIENT SETTING.
Favorite
PII-036
MASS BALANCE AND METABOLITE IDENTIFICATION OF VALEMETOSTAT AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY MALE SUBJECTS.
Favorite
PT-001
MAXIMUM LIKELIHOOD ESTIMATION OF RENAL TRANSPORTER ONTOGENY PROFILES FOR PEDIATRIC PBPK MODELING.
Favorite
EP-035
MECHANISTIC POPULATION PHARMACOKINETIC MODELLING OF RISDIPLAM FOR EXTRAPOLATION OF EXPOSURE AND CYP3A DRUG-DRUG INTERACTION IN NEONATES WITH SPINAL MUSCULAR ATROPHY.
Favorite
EP-011
METABOLIC PROFILE INVESTIGATION REVEALS WIDE VARIABILITY IN THE EXPOSURE OF ISONIAZID AND ITS HEPATOTOXIC METABOLITES IN TUBERCULOSIS PATIENTS.
Favorite
PII-060
METHOTREXATE POPULATION PHARMACOKINETICS IN PATIENTS WITH PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY.
Favorite
PII-049
MIRNA-125A ASSOCIATION WITH CARFILZOMIB-RELATED CARDIOVASCULAR ADVERSE EVENTS IN MULTIPLE MYELOMA PATIENTS: PROSPECTIVE OBSERVATION OF CARDIAC SAFETY WITH PROTEASOME INHIBITOR (PROTECT) STUDY.
Favorite
PII-061
MODEL INFORMED DRUG DEVELOPMENT (MIDD) TO SUPPORT AN ALTERNATIVE NIVOLUMAB DOSE AND SCHEDULE FOR ADVANCED MELANOMA.
Favorite
PII-096
MODEL INFORMED DRUG INTERACTION STUDY DESIGN FOR VESATOLIMOD AND CYP3A/P-GP MODULATORS USING PBPK.
Favorite
PII-062
MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Favorite
PWII-001
MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Favorite
EP-017
MODEL-INFORMED VANCOMYCIN DOSING TO ADDRESS DELAYED RENAL MATURATION IN INFANTS AND YOUNG CHILDREN WITH CONGENITAL HEART DISEASE.
Favorite
PII-063
MODELING AND SIMULATION TO SUPPORT APIXABAN DOSE RECOMMENDATION FOR THROMBOEMBOLISM PREVENTION IN PEDIATRIC SUBJECTS WITH CONGENITAL OR ACQUIRED HEART DISEASE REQUIRING ANTICOAGULATION – SAXOPHONE STUDY.
Favorite
PII-064
MODELING MORTALITY OF PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION USING SUPERVISED MACHINE LEARNING.
Favorite
LB-004
MOLNUPIRAVIR EXPOSURE-RESPONSE OF CLINICAL OUTCOMES IN TREATMENT OF COVID-19.
Favorite
LB-005
MOLNUPIRAVIR EXPOSURE-RESPONSE RELATIONSHIPS FOR CLINICAL OUTCOMES, VIROLOGY, AND MECHANISM OF ACTION BIOMARKERS ARE CONSISTENT IN TREATMENT OF COVID-19.
Favorite
PII-037
MTD IN DRUG COMBO: AN EXPERT CURATED MTD DATA SET FOR EFFICIENT DRUG COMBINATION PHASE 1 TRIAL DESIGN.
Favorite
PII-038
MULTICENTER PHARMACOKINETIC STUDY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER IN OLDER ADULTS AGED OVER 75 YEARS.
Favorite
N
PI-089
NATIONAL MEETING ON COMMUNITY ENGAGED RESEARCH TOWARDS PRECISION MEDICINE WITH AMERICAN INDIAN AND ALASKA NATIVE PEOPLE.
Favorite
PII-009
NOVEL IN VITRO TUBERCULOSIS ASSAYS AND THEIR UTILITY IN PREDICTING IN VIVO DRUG EFFICACY.
Favorite
O
PII-065
OPTIMAL DOSING OF RIFAPENTINE IN NOVEL 4-MONTH HIGH-DOSE RIFAPENTINE WITH MOXIFLOXACIN REGIMEN FOR THE TREATMENT OF DRUG-SUSCEPTIBLE TUBERCULOSIS.
Favorite
PT-018
OPTIMIZATION OF THE BETAMETHASONE DOSING REGIMEN DURING PREGNANCY: A COMBINED PLACENTA PERFUSION AND PREGNANCY PBPK MODELLING APPROACH.
Favorite
PT-002
OPTIMIZING CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY USING MULTIVARIATE DISEASE PROGRESSION MODELS THAT BRIDGE A FUNCTIONAL ENDPOINT AND MRI RELAXOGRAPHY OF FIVE LEG MUSCLES.
Favorite
RWE-006
OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Favorite
PT-022
OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Favorite
P
PII-028
PACIFIC BLUE DERIVATIVES OF PACLITAXEL AS FLUORESCENT PROBES OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B (OATP1B) TRANSPORTERS.
Favorite
PII-109
PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Favorite
RWE-009
PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Favorite
EP-021
PBPK MODELING OF A NARROW THERAPEUTIC INDEX DRUG AND APPLICATION IN PREDICTING DOSE ESCALATION SCENARIOS, FOOD EFFECT, DDI AND SPECIAL POPULATION.
Favorite
PII-097
PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Favorite
PWI-001
PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Favorite
PII-098
PBPK MODELING TO ASSESS DRUG-DRUG INTERACTION POTENTIAL OF VENGLUSTAT WITH CYP3A INHIBITORS.
Favorite
RWE-008
PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Favorite
PI-003
PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Favorite
LB-010
PEDIATRIC POPULATION PHARMACOKINETIC MODEL DEVELOPMENT FOR ORAL AMOXICILLIN AND CLAVULANIC: LEVERAGING LITERATURE DATA FOR MODEL-INFORMED DRUG EXPOSURE ANALYSIS IN YOUNG CHILDREN.
Favorite
PI-090
PERCEIVED BARRIERS AND FACILITATORS FOR MODEL-INFORMED DOSING IN PREGNANCY AMONG HEALTHCARE PRACTITIONERS AND PREGNANT WOMEN: A QUALITATIVE STUDY.
Favorite
PII-050
PHARMACOGENOMIC-AUGMENTED DRUG THERAPY IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW OF GENES AND A CASE FOR ARTIFICIAL INTELLIGENCE-AIDED GENOME-WIDE PANEL DESIGN.
Favorite
PII-051
PHARMACOGENOMICS OF ACAMPROSATE AND NALTREXONE THERAPY RESPONSE IN ALCOHOL USE DISORDER (AUD)
Favorite
PWIII-002
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Favorite
PI-030
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Favorite
PT-021
PHARMACOKINETIC (PK) BASIS OF STATIN DRUG-DRUG INTERACTION (DDI) INFORMATION IN FDA LABELS.
Favorite
PII-066
PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF PELUBIPROFEN TROMETHAMINE VERSUS PELUBIPROFEN IN HEALTHY SUBJECTS.
Favorite
PII-067
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING ANALYSIS OF JPI-547 IN PATIENTS WITH ADVANCED SOLID TUMOR.
Favorite
PII-068
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF OPIOID AND SEDATIVE/PSYCHOTROPIC DRUG EFFECTS ON VENTILATION AND PUPILLOMETRY.
Favorite
PII-069
PHARMACOKINETIC COMPARISON BETWEEN A FIXED-DOSE COMBINATION OF ATORVASTATIN/OMEGA-3 AND THE CORRESPONDING LOOSE COMBINATION IN HEALTHY KOREAN SUBJECTS.
Favorite
PII-014
PHARMACOKINETIC DRUG INTERACTION BETWEEN FEXUPRAZAN (DWP14012), A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN HEALTHY SUBJECTS.
Favorite
EP-031
PHARMACOKINETIC INTERACTION OF OMEGA-3 FATTY ACID 4 G AND ATORVASTATIN 40 MG.
Favorite
PII-070
PHARMACOKINETIC/PHARMACODYNAMIC ANALYSIS OF APIXABAN TO DETERMINE DOSING REGIMENS FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA TREATED WITH ASPARAGINASE: ANALYSIS FROM THE PREVAPIX STUDY.
Favorite
PII-071
PHARMACOKINETICS (PK) OF HZN-825, A SMALL MOLECULE SELECTIVE ANTAGONIST OF LPAR1, AND THE EFFECT OF FOOD IN HEALTHY ADULT SUBJECTS.
Favorite
PII-072
PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF ACETAMINOPHEN AND IBUPROFEN TO EVALUATE THE TIME TO PATENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM NEONATES.
Favorite
PII-015
PHARMACOKINETICS AND PHARMACODYNAMICS OF ENAVOGLIFLOZIN, AN SGLT-2 INHIBITOR, IN TYPE 2 DIABETES PATIENTS WITH IMPAIRED RENAL FUNCTION.
Favorite
PII-073
PHARMACOKINETICS AND PHARMACODYNAMICS OF EVOGLIPTIN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS.
Favorite
PI-006
PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED).
Favorite
PT-024
PHARMACOKINETICS AND TISSUE DISTRIBUTION OF A LIPID-BASED EXTENDED-RELEASE NANO-FORMULATION OF MO-OH-NAP TROPOLONE TO ENHANCE PULMONARY DELIVERY.
Favorite
PII-113
PHARMACOKINETICS OF AUMOLERTINIB IN HEALTHY CHINESE SUBJECTS AND NON-CHINESE SUBJECTS.
Favorite
PII-039
PHARMACOKINETICS OF INTESTINAL P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE WITH AND WITHOUT CONCOMITANT QUIZARTINIB.
Favorite
PII-074
PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY.
Favorite
PI-007
PHARMACOKINETICS OF REMDESIVIR AND ITS METABOLITES IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT.
Favorite
PII-016
PHARMACOKINETICS OF SHIP1 INHIBITORS IN MICE: COMPARISON OF IN SILICO AND IN VIVO PHARMACOKINETICS.
Favorite
PI-091
PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF CEDIROGANT FOLLOWING SINGLE AND MULTIPLE DOSES IN JAPANESE AND CHINESE HEALTHY VOLUNTEERS.
Favorite
PII-114
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF UPADACITINIB IN CHILDREN WITH ATOPIC DERMATITIS.
Favorite
PII-115
PHARMACOMETABOLOMICS OF STATIN DISPOSITION AND RESPONSE IN CHILDREN.
Favorite
PII-075
PHARMACOMETRICS (PMX) APPROACH TO SUPPORT PEDIATRIC DOSING FOR THE PAN-PI3K INHIBITOR COPANLISIB IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY SOLID TUMORS.
Favorite
PII-004
PHASE 1 DEVELOPMENT OF RAVAGALIMAB, AN ANTI CD40 MONOCLONAL ANTIBODY, TO SUPPORT DOSE SELECTION FOR PHASE 2.
Favorite
LB-013
PHYSIOLOGICALLY BASED ABSORPTION AND PHARMACOKINETIC MODEL FOR RIVOCERANIB AND ITS MAIN METABOLITE TO ASSESS POTENTIAL CYP3A4-MEDIATED DDI RISK.
Favorite
PII-099
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE DRUG-DRUG-GENE INTERACTION POTENTIAL OF BELZUTIFAN IN COMBINATION WITH CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN HEALTHY VOLUNTEERS.
Favorite
PWI-004
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Favorite
PII-116
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Favorite
PII-040
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING OF VALEMETOSTAT TO INFORM DOSE RECOMMENDATIONS WHEN CO-ADMINISTERED WITH CYP3A/P-GP MODULATORS.
Favorite
PWIII-001
PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Favorite
PI-031
PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Favorite
PII-117
PIPERACILLINE PHARMACOKINETICS AND PHARMACODYNAMICS IN PEDIATRIC PATIENTS WHO RECEIVED HIGH FREQUENCY PIPERACILLIN/TAZOBACTAM DOSING DURING SURGERY.
Favorite
PI-082
PLASMA METHYLMALONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH METHYLMALONIC ACIDEMIA.
Favorite
PII-106
PLASMA 3-HYDROXYPROPIONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH PROPIONIC ACIDEMIA.
Favorite
PI-008
POPULATION MODELING OF GSK3036656 PHARMACOKINETICS AND EARLY BACTERICIDAL ACTIVITY.
Favorite
PII-076
POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF VESATOLIMOD, A TLR7 AGONIST IN DEVELOPMENT FOR HIV CURE.
Favorite
LB-014
POPULATION PHARMACOKINETIC ANALYSIS OF PHASE 1 SUBCUTANEOUS LEVOTHYROXINE FORMULATION (XP-8121).
Favorite
EP-018
POPULATION PHARMACOKINETIC ANALYSIS OF RILZABRUTINIB IN HEALTHY SUBJECTS AND PATIENTS WITH PEMPHIGUS.
Favorite
PII-100
POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER.
Favorite
PII-077
POPULATION PHARMACOKINETIC MODELING AND SIMULATION OF TRANEXAMIC ACID IN ADULTS TRAUMA PATIENTS.
Favorite
PII-078
POPULATION PHARMACOKINETIC MODELING OF CLOFAZIMINE: CHARACTERIZING THE IMPACT OF CRYPTOSPORIDIOSIS-ASSOCIATED DIARRHEA ON ORAL DRUG PHARMACOKINETICS IN HIV-INFECTED ADULTS.
Favorite
PII-079
POPULATION PHARMACOKINETIC MODELING OF EVEROLIMUS AND INDIVIDUALIZED DOSING DEPENDING ON PROMISING COVARIATES IN LIVER TRANSPLANT RECIPIENTS.
Favorite
PT-016
POPULATION PHARMACOKINETIC MODELING TO GUIDE THE OPTIMAL DOSING FOR UNFRACTIONATED HEPARIN IN PEDIATRICS REQUIRING EXTRACORPOREAL MEMBRANE OXYGENATION.
Favorite
EP-023
POPULATION PHARMACOKINETIC MODELLING TO CONFIRM WEIGHT-BASED BANDED DOSING AND EXPOSURE-RESPONSE EFFICACY ANALYSES TO SUPPORT TROFINETIDE TREATMENT IN RETT SYNDROME.
Favorite
EP-024
POPULATION PHARMACOKINETIC MODELLING TO PREDICT TROFINETIDE EXPOSURE AND EXPOSURE-RESPONSE SAFETY ANALYSES IN GIRLS WITH RETT SYNDROME AGED 2–4 YEARS.
Favorite
PII-080
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA.
Favorite
PII-081
POPULATION PHARMACOKINETICS (PK) OF ETHAMBUTOL IN TUBERCULOSIS PATIENTS – TUBERCULOSIS TRIALS CONSORTIUM (TBTC) STUDY A5349/S31.
Favorite
PII-082
POPULATION PHARMACOKINETICS (POPPK) OF SACITUZUMAB GOVITECAN (SG) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) OR OTHER SOLID TUMORS.
Favorite
EP-008
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TREMELIMUMAB 300 MG SINGLE DOSE COMBINED WITH DURVALUMAB 1500 MG EVERY 4 WEEKS (STRIDE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA.
Favorite
EP-034
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Favorite
PI-105
POPULATION PHARMACOKINETICS OF FS-1502, AN HER2 ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH HER2 EXPRESSED ADVANCED MALIGNANT SOLID TUMORS.
Favorite
PII-083
POPULATION PHARMACOKINETICS OF GS-3583 IN HEALTHY VOLUNTEERS AND PATIENTS WITH ADVANCED SOLID TUMORS.
Favorite
PT-012
POPULATION PHARMACOKINETICS OF ISONIAZID IN TBTC STUDY 31/ACTG A5349.
Favorite
PII-084
POPULATION PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS.
Favorite
PII-085
POPULATION-BASED EFFICACY MODELING OF OMALIZUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PERSISTENT INADEQUATELY CONTROLLED ALLERGIC ASTHMA.
Favorite
LB-001
POSITIVE CORRELATION BETWEEN ORGANIC ANION TRANSPORTER 1B FUNCTION INDICATED BY PLASMA CONCENTRATION OF COPROPORPHYRIN-I AND BLOOD CONCENTRATION OF CYCLOSPORIN A IN REAL-WORLD PATIENTS.
Favorite
PI-102
POST MARKETING COMMITMENT OR REQUIREMENT (PMC/R) FOR RECENT APPROVED DRUG PRODUCTS: SUMMARY FROM CLINICAL PHARMACOLOGY (CP) PERSPECTIVES.
Favorite
PII-041
POTENTIAL STRATEGIES TO OPTIMIZE CAR-T CELL EXPOSURE IN ABSENCE OF DOSE-EXPOSURE RELATIONSHIPS LEVERAGING CELL KINETIC/DYNAMIC MODELS.
Favorite
EP-030
PRECLINICAL IN-VITRO ASSAYS EVALUATING PROTEIN DEGRADERS (PDS) ASSOCIATE WITH ORAL BIOAVAILABILITY AND VOLUME OF DISTRIBUTION IN TISSUES.
Favorite
PII-101
PREDICTING CLINICAL EFFECTS OF CYP3A4 PERPETRATORS ON PIRTOBRUTINIB PHARMACOKINETICS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING.
Favorite
RWE-007
PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Favorite
PT-010
PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Favorite
PII-102
PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN.
Favorite
PI-009
PREDICTORS AFFECTING SPUTUM CULTURE CONVERSION IN PATIENTS WITH DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS TREATED WITH A SHORTENED DRUG REGIMEN.
Favorite
PT-004
PROSPECTIVE VALIDATION OF MAXIMUM A POSTERIORI-BAYESIAN ESTIMATION OF TACROLIMUS EXPOSURE IN STABLE KIDNEY TRANSPLANT RECIPIENTS.
Favorite
PII-052
PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY.
Favorite
PII-118
PROTEOMIC- AND BIOINFORMATIC- BASED CHARACTERIZATION OF A PRECLINICAL RODENT MODEL OF PREECLAMPSIA.
Favorite
Q
PII-021
QUANTIFYING THE EFFECTS OF ALCOHOL USE ON DRIED BLOOD SPOT CONCENTRATIONS OF SOFOSBUVIR’S ACTIVE METABOLITE, 007-TP, IN PERSONS WITH HEPATITIS C USING PHOSPHATIDYLETHANOL AS AN OBJECTIVE BIOMARKER OF ALCOHOL CONSUMPTION.
Favorite
PII-086
QUANTITATIVE EFFECT OF CYP2C9 INDUCTION BY DICLOXACILLIN ON THE NARROW THERAPEUTIC DRUGS: PHENYTOIN AND WARFARIN.
Favorite
PII-126
QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING DILISYM INFORMED SAFE DOSE SELECTION OF EMVODODSTAT IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS.
Favorite
R
PI-092
RECENT TRENDS IN PEDIATRIC DOSING STRATEGY FROM 2000-2019: A NATURAL LANGUAGE PROCESSING/DRUG LABEL ANALYSIS.
Favorite
PWIV-002
RECENT TRENDS IN PEDIATRIC DOSING STRATEGY FROM 2000-2019: A NATURAL LANGUAGE PROCESSING/DRUG LABEL ANALYSIS.
Favorite
PII-103
REGISTERED DIGOXIN DOSES FOR CHILDREN DO NOT LEAD TO OPTIMAL EXPOSURE: A PBPK STUDY.
Favorite
LB-002
RESIDUAL C-PEPTIDE IS ASSOCIATED WITH LOWER HYPOGLYCEMIA RISK IN NEW-ONSET TYPE 1 DIABETES – A POOLED ANALYSIS OF 2780 ADULTS AND CHILDREN.
Favorite
PII-017
REVIEW OF BISPECIFIC ANTIBODIES’ IMMUNOGENICITY IN CLINICAL DEVELOPMENT.
Favorite
PII-022
RIFAPENTINE EXPOSURE-RESPONSE RELATIONSHIPS ARE DIFFERENT FOR PHASE II AND PHASE III PRIMARY EFFICACY ENDPOINTS IN TUBERCULOSIS CLINICAL TRIALS.
Favorite
PII-023
RISK OF QT PROLONGATION WITH OLIGONUCLEOTIDES: A REVIEW OF PUBLISHED EVIDENCE.
Favorite
PT-019
ROLE OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B (OATP1B) IN HEPATIC UPTAKE AND ADVERSE EFFECTS OF AROMATASE INHIBITORS (AIS).
Favorite
S
PI-004
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A NOVEL MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENT, HNP-2006, AFTER A SINGLE INTRAVENOUS ADMINISTRATION IN HEALTHY SUBJECTS.
Favorite
EP-022
SELECTION OF COMPARISON DRUGS FOR ASSESSING THE CARDIAC PROTECTIVE PROPERTIES OF DRUG CANDIDATES.
Favorite
PII-032
SUBSTANCE USE DISORDERS: GLUCOCORTICOID SIGNALING REGULATES THE EXPRESSION OF PTPRD IN HUMAN CNS CELLS.
Favorite
T
PI-100
THE DRUG-DRUG INTERACTION (DDI) EFFECT OF STEADY STATE ITRACONAZOLE EXPOSURE ON SINGLE DOSE PHARMACOKINETICS (PK) OF LAZERTINIB.
Favorite
PII-087
THE EFFECT OF FOOD ON T3 AND T4 BIOAVAILABILITY AND THE DOSE PROPORTIONALITY OF ARMOUR THYROID.
Favorite
LB-011
THE EFFECT OF NASAL CONGESTION ON THE BIOAVAILABILITY OF INTRANASALLY ADMINISTERED EPINEPHRINE IN HEALTHY ADULT SUBJECTS WITH SEASONAL ALLERGIES.
Favorite
PII-088
THE EFFECT OF UGT INHIBITION ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES.
Favorite
PII-033
THE EFFECTS OF AN ACUTE ORAL DOSE OF METHAMPHETAMINE ON NEURAL ACTIVATION DURING PERFORMANCE ON A MONETARY REWARD TASK IN HEALTHY ADULTS.
Favorite
PII-089
THE EFFECTS OF CYP3A INDUCTION AND INHIBITION ON ZURANOLONE PHARMACOKINETICS IN HEALTHY ADULTS.
Favorite
PII-029
THE EFFECTS OF RIFAMPICIN AS AN ORGANIC ANION TRANSPORTING POLYPEPTIDES INHIBITOR AND FEBUXOSTAT AS A BREAST CANCER RESISTANCE PROTEIN INHIBITOR ON PHARMACOKINETICS OF METHOTREXATE IN HEALTHY SUBJECTS.
Favorite
PI-032
THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.
Favorite
PWIV-005
THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.
Favorite
PII-119
THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Favorite
RWE-011
THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Favorite
PI-098
THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTICS (MPRINT) KNOWLEDGEBASE AND PORTAL.
Favorite
PII-018
THE PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VUTIGLABRIDIN, A SYNTHETIC GLABRIDIN DERIVATIVE, AFTER MULTIPLE ADMINISTRATION IN OBESE SUBJECTS.
Favorite
PII-010
THE REPLACEMENT, REDUCTION AND REFINEMENT PRINCIPLE APPLIED TO THE VINTAGE ORAL TYRAMINE CHALLENGE TEST OF MAO INHIBITORS; EVALUATION OF A REFINED AND REDUCED DESIGN WITH TYRAMINE CMAX REPLACING BLOOD PRESSURE RESPONSE.
Favorite
PII-005
THERAPEUTIC DRUG MONITORING CAN GUIDE THE INTRAVENOUS-TO-SUBCUTANEOUS SWITCH OF INFLIXIMAB AND VEDOLIZUMAB: A PHARMACOKINETIC SIMULATION STUDY.
Favorite
PT-026
TRANSCRIPTOMIC PROFILING OF PTRPD KNOCK-DOWN IN HUMAN IPSC-DERIVED NEURONS REVEALED A ROLE IN ALCOHOL USE DISORDER DRUG TREATMENT RESPONSE.
Favorite
PII-042
TRANSLATABILITY OF IN VITRO POTENCY TO CLINICALLY EFFICACIOUS EXPOSURE FOR MOLECULARLY TARGETED SMALL MOLECULE ONCOLOGY DRUGS.
Favorite
PII-043
TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Favorite
PWII-003
TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Favorite
PII-024
TRANSLATIONAL MODEL-BASED META-ANALYSIS - A POWERFUL QUANTITATIVE TOOL IN DEVELOPING VACCINES AGAINST SARS-COV-2 VARIANTS.
Favorite
PII-090
TRANSLATIONAL PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION TO PREDICT EFFICACIOUS HUMAN DOSES FOR YH35324 (GI-301)
Favorite
PII-091
TRANSLATIONAL TOOL FOR PREDICTING THE EARLY BACTERICIDAL ACTIVITY OF SUTEZOLID FOR THE TREATMENT OF TUBERCULOSIS.
Favorite
PT-015
TRANSPORT AND KINASE DEPENDENT REGULATION OF TYROSINE KINASE INHIBITOR INDUCED CARDIOTOXICITY.
Favorite
U
PII-044
UNDERSTANDING METHOTREXATE CONCENTRATIONS AND ASSOCIATED TOXICITIES TO GUIDE SUPPORTIVE CARE IN PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL).
Favorite
PII-025
UNDERSTANDING THE PK/PD RELATIONSHIP FOR THE METALLO-BETA-LACTAMASE (MBL) INHIBITOR MK-3402 AND PRELIMINARY DOSE PROJECTION FOR PATIENTS WITH MDR GRAM-NEGATIVE INFECTIONS.
Favorite
PII-110
US FDA POSTMARKETING REQUIREMENTS AND COMMITMENTS RELATED TO DRUG DISPOSITION IN LACTATION AND PREGNANCY.
Favorite
PII-045
USE OF A POPULATION PHARMACOKINETIC MODELLING AND SIMULATION APPROACH TO IDENTIFY FLAT DOSES OF DOMVANALIMAB IN PHASE 3 STUDIES.
Favorite
RWE-001
USING REAL WORLD EVIDENCE (RWE) TO ASSESS DRUG-DRUG INTERACTION (DDI) BETWEEN PAXLOVID AND THE TOP 100 PRESCRIBED DRUGS IN THE US.
Favorite
PI-005
USING REAL WORLD EVIDENCE (RWE) TO ASSESS DRUG-DRUG INTERACTION (DDI) BETWEEN PAXLOVID AND THE TOP 100 PRESCRIBED DRUGS IN THE US.
Favorite
V
PT-007
VALIDATING THE PROTECTIVE CONCENTRATION OF PIPERAQUINE FOR MALARIA PREVENTION IN PREGNANT UGANDAN WOMEN.
Favorite
Y
PII-092
YOU MUST CHOOSE, BUT CHOOSE WISELY – PHASE 2 DOSE SELECTION FOR INBRX-109, A TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST ANTIBODY.
Favorite
Z
PII-093
ZURANOLONE, A NOVEL GABAA POSITIVE ALLOSTERIC MODULATOR, DOES NOT PROLONG THE QT INTERVAL.
Favorite
